Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gallus BioPharmaceuticals has entered into collaboration partnership with Xcellerex to expand its cGMP biomanufacturing capacity by acquiring Xcellerex FlexFactory GMP manufacturing platform suite.
Subscribe to our email newsletter
Under the agreement, Gallus is acquiring several Xcellerex bioproduction systems for new suites and laboratories at its existing manufacturing facility.
The strategic collaboration will provide Gallus with manufacturing and laboratory technology to expand its contract manufacturing business.
Along with single-use XDR bioreactors to quickly expand capabilities in an existing commercial manufacturing suite, Gallus is acquiring small scale 10L bioreactors for its expanded development laboratory and a turnkey FlexFactory cGMP manufacturing line with XDR single-use bioreactors up to 2000 liter scale for clinical supply.
Xcellerex’s FlexFactory is a portable biomanufacturing platform, based on application like single-use technologies, controlled environmental modules (CEMs) and advanced process automation including electronic batch records.
Xcellerex claims the FlexFactory eliminates clean- and steam-in-place requirements and clean room infrastructure, simplifies facility design, reduces manufacturing footprint and capital investment and creates gains in operating environmental friendliness.
Gallus president and CEO Mark Bamforth said it has a contract manufacturing business model that enables them to respond to clients’ changing capacity needs and achieve high quality production at a competitive price.
"This strategic investment provides us with additional manufacturing capacity and scale-up capabilities to deliver development, clinical and commercial products and services," Bamforth said.